Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel plus panitumumab vs paclitaxel alone in relapsed or refractory urothelial cancer
2014-000857-35Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Paclitaxel + panitumumab with Paclitaxel alone (2 arms). Primary endpoint: Progression-free survival. Started May 2015; status: terminated.
02
Drugs
paclitaxelpanitumumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2014-000857-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000857-35.